Regeneron and Tessera Partner in $275 Million Deal to Develop Gene Editing for Alpha-1 Antitrypsin Deficiency

Regeneron Pharmaceuticals has entered into a $275 million partnership with Tessera Therapeutics to advance gene editing technologies targeting alpha-1 antitrypsin deficiency (AATD). The collaboration centers on the in vivo editor TSRA-196, which has demonstrated significant potential in preclinical studies by effectively editing SERPINA1, the genetic locus associated with AATD.

Alpha-1 antitrypsin deficiency is a rare genetic disorder that can lead to lung and liver disease. Regeneron’s agreement with Tessera aims to leverage TSRA-196’s capabilities to address this condition through precise genetic modifications. Preclinical research indicates that TSRA-196 achieves robust editing at the SERPINA1 locus, suggesting it could play a critical role in developing treatments for AATD.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

Related posts:

Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment Spencer Jones Discusses December 2023 Trends in Digital Health and Personalized Medicine Biocon Foundation Begins Construction of New Building for Government High School in Kodamballi to Benefit 250 Students Clinicians Urged to Address Sex-Based Differences in Antibiotic Dosing for Sepsis Care

Author

GOAI